Pediatric and adult patients with ME/CFS following COVID-19: A structured approach to diagnosis using the Munich Berlin Symptom Questionnaire (MBSQ). — CFSMEATLAS
Pediatric and adult patients with ME/CFS following COVID-19: A structured approach to diagnosis using the Munich Berlin Symptom Questionnaire (MBSQ).
Peo, Laura-Carlotta, Wiehler, Katharina, Paulick, Johannes et al. · European journal of pediatrics · 2024 · DOI
Quick Summary
This study looked at young people (ages 11-25) who developed ME/CFS after having COVID-19, even when their initial infection was mild or asymptomatic. Researchers created new questionnaires called the Munich Berlin Symptom Questionnaires (MBSQs) to help doctors diagnose ME/CFS more easily and consistently. The study found that ten young patients had severe problems with daily activities and quality of life after developing ME/CFS following COVID-19.
Why It Matters
This study provides the first documented cases of ME/CFS in children under 19 years following COVID-19, expanding awareness that pediatric post-COVID patients can develop this serious condition. The newly developed MBSQ tools offer clinicians a structured, validated approach to diagnosing ME/CFS, which is particularly important given that pediatric ME/CFS can be easily missed or misdiagnosed.
Observed Findings
Ten patients aged 11-25 years were diagnosed with ME/CFS following asymptomatic SARS-CoV-2 infection or mild-to-moderate COVID-19
Patients demonstrated severe impairments in daily activities and health-related quality of life on validated outcome measures
The MBSQs successfully identified ME/CFS according to multiple established diagnostic criteria
Pediatric ME/CFS following COVID-19 presented with chronic fatigue and post-exertional malaise as primary symptoms
Inferred Conclusions
ME/CFS can develop in children and adolescents younger than 18 years after SARS-CoV-2 infection, not just in adults
Structured diagnostic questionnaires like the MBSQ are valuable tools for identifying ME/CFS in pediatric post-COVID clinics
The MBSQs may be applicable beyond post-COVID conditions to other post-infection and post-vaccination syndromes
Remaining Questions
What is the actual prevalence of ME/CFS in pediatric post-COVID populations, and what factors predict which patients will develop ME/CFS?
How do the MBSQ questionnaires perform in prospective validation studies across larger, diverse pediatric populations?
Are there biological differences in ME/CFS pathogenesis between pediatric and adult patients, or between post-COVID ME/CFS and ME/CFS from other triggers?
What This Study Does Not Prove
This case series cannot establish how common ME/CFS is in pediatric post-COVID populations, as it describes only ten selected patients. The study does not prove that COVID-19 directly causes ME/CFS (only temporal association), nor does it clarify which patient characteristics or infection factors increase risk for developing ME/CFS.